Eligible patients

KISQALI: approved in the broadest * population including all N+ and high-risk N0 patients ^(1-4)

Patients with HR+/HER2– EBC: ^(1,3)

* Of all approved CDK4/6i. ^(1-4)

^‡ Grade 3 or grade 2 with additional risk factors, such as Ki-67 score ≥20% or defined as an Oncotype DX Breast Recurrence Score of ≥26, or Prosigna/PAM50, MammaPrint, or EndoPredict EPclin high-risk scores. ⁽³⁾

Abbreviations

CDK4/6i, cyclin-dependent kinase 4 and 6 inhibitor; EBC, early breast cancer; HER2–, human epidermal growth factor receptor 2 negative; HR+, hormone receptor positive; N0, no nodal involvement; N1, 1–3 axillary lymph nodes; N2, 4–9 axillary lymph nodes; N3, ≥10 axillary lymph nodes or collarbone lymph nodes; T, tumour; T2, tumour is more than 2 cm but less than 5 cm; T3, tumour is more than 5 cm; T4, tumour of any size growing into the chest wall or skin, includes inflammatory breast cancer.

References

KISQALI (ribociclib). Summary of Product Characteristics.
Verzenios (abemaciclib). Summary of Product Characteristics.
Slamon DJ, et al. Ther Adv Med Oncol. 2023;15:1–16.
Harbeck N, et al. Ann Oncol. 2021: 32:1571–1581.

Eligible patients

KISQALI: approved in the broadest * population including all N+ and high-risk N0 patients (1-4)

KISQALI: approved in the broadest * population including all N+ and high-risk N0 patients ^(1-4)